Polymeric Ig receptor: Defender of the fort or Trojan Horse?  by Kaetzel, Charlotte S
Dispatch R35
Polymeric Ig receptor: Defender of the fort or Trojan Horse?
Charlotte S. Kaetzel
The polymeric immunoglobulin receptor (pIgR) is
important in host defense, transporting antibodies
across mucosal epithelial cells. Recent work has shown
that, using a protein that binds directly to the pIgR,
Streptococcus pneumoniae can co-opt the transcytosis
machinery and gain entry into airway epithelial cells.
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Streptococcus pneumoniae is an important human pathogen,
causing diseases ranging from relatively mild otitis media
to potentially fatal sepsis, pneumonia and meningitis [1].
The upper respiratory tracts of many healthy individuals
are colonized with non-invasive S. pneumoniae. The balance
between colonization and invasion relies on an uneasy
truce between the opposing forces of host defense and
bacterial virulence factors. The consequences of violating
this truce are disastrous to both the host and the unwel-
come guests; a massive inflammatory response is highly
effective in clearing the pneumococci, but the resultant
tissue damage can lead to significant morbidity and mor-
tality for the host. 
Secretory antibodies of the immunoglobulin A (IgA)
class, together with non-specific defense mechanisms,
are gen-erally effective at preventing invasion of upper
airway epithelium and blocking access of pneumococci
to the bronchi and lungs. These defenses may be inade-
quate, however, in infants, the elderly and immunocom-
pro-mised individuals. Major pneumococcal virulence
factors include the polysaccharide capsule, cell-wall con-
stituents and a variety of bacterial proteins that facilitate
adhesion or inhibit host defense mechanisms. Included
among these virulence factors are a family of choline-
binding proteins, which are secreted by the pneumo-
cocci and anchored to the bacterial cell wall by binding
to phosphorylcholine moieties of teichoic and lipotei-
choic acid [2]. 
A novel aspect of human–pneumococcal relations has
recently been revealed by the characterization of the
S. pneumoniae choline-binding proteins CbpA and SpsA,
which specifically interact with the ‘secretory component’
of human secretory IgA [3–5]. These pneumococcal pro-
teins have highly homologous carboxyl termini that include
a large choline-binding region and an internal element that
is necessary and sufficient for binding secretory component
(Figure 1). The functions of the divergent amino termini of
these proteins are unclear at present. 
Independent studies [4,5], using different strains of S. pneu-
moniae, have shown that insertional inactivation of the
gene for either CbpA or SpsA causes a total loss of binding
to secretory component, suggesting that the proteins may
be encoded by allelic forms of a single gene with signifi-
cant sequence variation among strains. The choline-binding
proteins appear to play an important role in S. pneumoniae
pathogenesis: recent results [5] have shown that, by
binding directly to the polymeric immunoglobulin recep-
tor (pIgR), which transports antibodies across mucosal
epithelial cells, CbpA/SpsA allows the invading bacterial
cells to co-opt the transcytosis machinery and gain entry
into airway epithelial cells.
Polymeric immunoglobulin receptor — defender of the fort
Secretory IgA is the first line of specific immune defense
that protects the mucous membranes from inhaled,
ingested and sexually transmitted pathogens [6–8]. Local
plasma cells in mucosal tissues secrete predominantly
polymeric IgA, which binds to the pIgR on the basolateral
surface of mucosal epithelial cells (Figure 2) [9]. The
pIgR mediates transport of polymeric IgA across polar-
ized epithelial cells, allowing cleavage and release of
secretory component, either free or bound covalently to
IgA (Figure 3). The association with secretory component
has been shown to protect secretory IgA antibodies from
proteolytic degradation. While pIgR can be internalized
from the apical surface of a mucosal epithelial cell and
Figure 1
The domain structures of CbpA and SpsA, based on an alignment of
the protein sequences of CbpA from strain R6x of S. pneumoniae and
SpsA from strain 1 of S. pneumoniae. The proteins are composed of a
divergent amino-terminal region (white), a minimal pIgR/secretory
component-binding domain of about 105 residues (yellow), a linker
region (green), nine or ten choline-binding repeats (blue) and a short
carboxy-terminal region (red).
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transported in retrograde fashion to the basolateral surface,
this pathway is clearly less efficient than basolateral-to-
apical transcytosis. 
Protection against potential pathogens can occur at three
levels during or following pIgR-mediated transport of
polymeric IgA [9,10]. Firstly, secretory IgA in external
secretions acts as an immunological barrier, preventing
adherence and invasion of the epithelial layer by microor-
ganisms. Secondly, polymeric IgA can neutralize viruses,
and possibly also bacteria, intracellularly during pIgR-
mediated transcytosis. Finally, pIgR can transport large
immune complexes, and probably also microorganisms
coated with polymeric IgA, from the basolateral surface of
a mucosal epithelial cell to the apical surface, allowing for
safe disposal of harmful antigens and potential pathogens.
A notable feature of the pIgR transcytosis pathway is the
efficient transport of unoccupied receptors, leading to the
release of free secretory component at the apical surface of
a mucosal epithelial cell (Figure 3). Human milk, bile and
respiratory secretions contain significant levels of free IgA
secretory component, suggesting that this by-product of
pIgR transcytosis may serve biological functions distinct
from its association with IgA [9]. Interestingly, during
human fetal development and early infancy, production
of pIgR and secretory component precedes that of IgA
by several months [11]. The recent findings [3–5] that the
pneumococcal protein CbpA/SpsA interacts specifically
with secretory component suggests that free secretory com-
ponent may also have an important defense role, by block-
ing adherence of S. pneumoniae to pIgR on surfaces of
mucosal epithelial cells. 
Zhang et al. [5] found that preincubation of S. pneumoniae
with free secretory component prevented subsequent
invasion by the bacterial cells of cultured human pharyngeal
carcinoma cells. The presence of free IgA secretory com-
ponent in respiratory secretions and in breast milk may
therefore be important in protecting infants who have not
yet developed specific IgA antibodies from pneumococcal
infections. The pIgR can thus defend the ‘fort’ against
pneumococcal invasion in two ways: by providing a trans-
port mechanism for protective IgA antibodies, and by pro-
viding free secretory component to block bacterial
adherence.
The polymeric immunoglobulin receptor as a Trojan Horse
The ability of cell surface pIgR to bind pneumococcal
CbpA/SpsA is, for both the pathogen and host, a double-
edged sword. The binding of S. pneumoniae CbpA/SpsA to
pIgR on the nasopharyngeal epithelium, its preferred
niche, presumably provides a mechanism for colonization.
Three factors should normally prevent pIgR-mediated
internalization of pneumococci: cleavage of pIgR from the
apical surface; the relative inefficiency of apical-to-baso-
lateral transcytosis; and the presence of free secretory
component and secretory IgA antibodies in the respiratory
secretions. But an imbalance in any of these factors, or an
overwhelming infection with pneumococci, could tip the
scales in favor of invasion.
Zhang et al. [5] have convincingly demonstrated that
the production of pIgR by cultured epithelial cells pro-
moted invasion and apical-to-basolateral transcytosis of
wild-type, but not CbpA-deficient, S. pneumoniae. Invasion
was blocked by antibodies against either CbpA or secre-
tory component, or by free secretory component itself,
demonstrating the specificity of the pIgR–CbpA interac-
tion. Furthermore, the enhancement of pIgR produc-
tion by interferon-γ caused a corresponding increase in
pneumococcal invasion. An inflammatory response to
pneumococcal infection could therefore actually enhance
pIgR-mediated bacterial invasion. 
R36 Current Biology Vol 11 No 1
Figure 2
Structure of the polymeric immunoglobulin
receptor (pIgR). The pIgR is a transmembrane
receptor with five extracellular Ig homology
domains and a long cytoplasmic tail
containing signals for intracellular sorting and
endocytosis [9]. Extracellular domains 1, 4
and 5 (yellow) are highly conserved among
species, and contain signals for non-covalent
and disulfide bonding to polymeric IgA.
Domains 2 and 3 (blue) are less conserved,
and are absent in some splice variants of
rabbit pIgR. Cleavage of full-length pIgR to
release the soluble secretory component (SC)
occurs within the linker connecting domain 5
to the transmembrane region. S. pneumoniae
CbpA and SpsA proteins bind to secretory
component region of full-length pIgR, soluble
secretory component and secretory IgA [3–5].
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The pIgR would thus seem to facilitate pneumococcal
invasion, and the in vivo significance of this was tested by
measuring the outcome of pneumococcal infection in two
models of deficient pIgR transcytosis. Mice deficient in
pIgR exhibited decreased nasal colonization by S. pneumo-
niae relative to wild-type, and mice deficient in the protein
tyrosine kinase p62yes, which is required for normal pIgR
transcytosis [12], showed a delayed onset of bacteremia
relative to wild-type. Furthermore, in an earlier study [2],
CbpA-deficient pneumococci were found to colonize the
infant rat nasopharynx at a 100-fold lower efficiency than
wild-type pneumococci. The mechanisms underlying
these in vivo effects are unclear in light of recent evidence
[4] that pneumococcal SpsA protein does not bind mouse
or rat secretory component or secretory IgA. It is possible,
however, that a level of binding below the detection limit
of in vitro assays might still be sufficient to mediate in vivo
effects. Alternatively, the pIgR transcytosis pathway could
be exploited if polymeric IgA were bound to the surface of
the pneumococci.
Other results have implicated the pIgR transcytosis
pathway in promoting, rather than preventing, invasion by
pathogens. Polymeric IgA antibodies have been reported
[13,14] to facilitate entry of Epstein-Barr virus (EBV) into
epithelial cells by pIgR-mediated endocytosis, although
the outcome of virus internalization — transcytosis or pro-
ductive infection — depended on the degree of epithelial
cell polarization. Other studies [15,16] demonstrated that
EBV could infect pIgR-expressing nasopharyngeal carci-
noma cells in the presence, but not in the absence, of
EBV-specific polymeric IgA. Furthermore, pIgR protein
and EBV RNA were found to be colocalized in biopsies of
nasopharyngeal carcinoma.
A recent study [17] found that the level of vaginal disease
following infection by type 2 Herpes Simplex Virus is
reduced, relative to wild-type, in J-chain-deficient mice,
which cannot assemble polymeric immunoglobulins and
are therefore deficient in pIgR-mediated transcytosis. The
common theme in these viral infections is that virus-
specific polymeric IgA appears to act as a ‘bridge’ between
pathogen and pIgR. The recent demonstration [5] of a
direct interaction between pneumococcal CbpA/SpsA and
pIgR suggests a novel and devious mechanism by which
bacteria may use pIgR as a ‘Trojan Horse’ to invade the
unsuspecting epithelial cell. 
An evolutionary perspective
From the point of view of S. pneumoniae, the most benefi-
cial outcome of interaction with its host is colonization, not
invasion. The bacteria would therefore gain an adaptive
advantage by producing a surface protein that can bind to a
cell-surface protein expressed at high levels on the host
nasopharyngeal epithelium. The pIgR fits this bill nicely,
as it is produced at high levels in the upper, but not the
lower, respiratory tract. Several observations support the
view that the CbpA/SpsA–pIgR interaction is of adaptive
significance. Rosenow et al. [2] reported that the level of
CbpA was higher in transparent, compared to opaque, vari-
ants of S. pneumoniae strain R6x. They suggested that
CbpA is subject to phase variation and is a marker for colo-
nization-proficient phase variants of pneumococci. Ham-
merschmidt et al. [3] found that SpsA is produced by 73%
of tested S. pneumoniae clinical isolates that they tested,
and is highly conserved between different serotypes.
The hexapeptide motif YRNYPT within the carboxy-
terminal domain of SpsA that binds pIgR/secretory com-
ponent was shown to be sufficient, as a hexapeptide, to
inhibit the interaction between S. pneumoniae and secre-
tory IgA [4]. The sequence RRNYPT occurs twice in the
CbpA sequence, at positions 125 and 287. The latter
occurrence is analogous to the location of the motif in
SpsA, and the former is in an upstream region, unique to
Figure 3
The pathway of transcytosis. The pIgR protein is initially targeted to the
basolateral surface of polarized epithelial cells. Internalization signals in
its carboxy-terminal domain cause pIgR — with or without polymeric IgA
(pIgA) or IgM ligand — to be sorted into coated pits and endocytosed. In
the endosomal compartment, pIgR can be sorted into vesicles for
transcytosis to the apical surface or recycled to the basolateral surface.
At the apical surface, a protease cleaves free or polymeric IgA-bound
pIgR, releasing free secretory component (SC) or secretory IgA (S-IgA)
into the extracellular secretions. Uncleaved pIgR can be internalized
from the apical surface, then recycled to that surface or transcytosed to
the basolateral surface. By binding to pIgR, S. pneumoniae can co-opt
the transcytosis machinery and breach the epithelial barrier.
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CbpA, that is highly homologous to the pIgR/secretory
component-binding domain [5]. The lack of requirement
for the amino-terminal domains of CbpA of SpsA for
binding to either the pIgR/secretory component or choline
suggests that sequence divergence in this region might be
permissible and perhaps beneficial from the point of view
of evading host immune responses.
The interaction between pIgR/secretory component and
pneumococcal CbpA/SpsA appears to be a uniquely
human trait. Using several in vitro protein-binding assays,
Hammerschmidt et al. [4] demonstrated that SpsA binds to
secretory component and secretory IgA from humans, but
not rabbits, rats, mice or guinea pigs. Using cell-culture
models of adherence and invasion, Zhang et al. [5] showed
that CbpA interacts with human, but not rabbit, pIgR.
The sequence of pIgR has now been determined for six
mammalian and one marsupial species, revealing signifi-
cant regions of conservation and divergence. Rabbit pIgR
is the most diverged in sequence from human pIgR, con-
sistent with the observation that cells producing rabbit
pIgR were non-permissive for S. pneumoniae invasion. 
The most divergent segment of the pIgR protein among all
the species is found within extracellular domains 2 and 3,
which can be absent, as a result of alternative splicing, from
rabbit pIgR without loss of function [9,18]. Three amino
acid polymorphisms in human pIgR sequence have been
identified from protein [19] or mRNA sequences. While
the S357G and A562V polymorphisms are conservative and
unlikely to alter pIgR function, the L183R polymorphism,
which replaces a hydrophobic residue with a basic one,
occurs within the highly divergent domain 2. Significantly,
mouse, rat and rabbit pIgR, which appear not to bind
CbpA/SpsA, differ from human pIgR at this residue. To
increase our understanding of the nature of S. pneumoniae
adhesion and invasion, it will be important to locate the
binding site for CbpA/SpsA on pIgR, and to determine the
effects of pIgR polymorphisms on CbpA/SpsA binding.
The future of human–pneumococcal relations
The optimal approach for preventing human disease caused
by S. pneumoniae would be the development of a vaccine
that prevents both colonization and disease. Current
vaccine strategies, including the highly effective polysac-
charide–protein conjugate vaccines [20], have primarily tar-
geted the polysaccharide capsule. A serious limitation of
polysaccharide-based vaccines is the high variability of
polysaccharide structure among serotypes of S. pneumoniae,
more than 80 of which have been identified. A vaccine tar-
geted at the CbpA/SpsA molecule, especially at its con-
served domain that binds the pIgR/IgA secretory
component, would have the potential to block both colo-
nization and invasion. The identification of a peptide that is
capable of blocking S. pneumoniae adhesion has exciting
implications for vaccine development. This approach, in
conjunction with established polysaccharide conjugate vac-
cines, holds promise for providing broad spectrum protec-
tion against invasive disease caused by S. pneumoniae.
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